16-06-2020 12:00 via medpagetoday.com

Biologic Effective in Light Chain Amyloidosis

(MedPage Today) -- Adding the anti-CD38 agent daratumumab (Darzalex) to cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) improved the rate of hematologic complete response and delayed the time to major organ deterioration progression...
Read more »